ArticleVaccines2022
Pivotal
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06047821 (The Incidence and Burden of Shigella Diarrhea in Children Aged 6-35 Months), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Incidence and Burden of Shigella Diarrhea in Children Aged 6-35 Months: the Enterics for Global Health (EFGH) - Shigella Burden Study
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Consequences of Shigella infection in young children: a systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- Review
- Kinetics of Enteric Pathogen Quantity During Acute Diarrhea in Children in Resource-Limited Settings.Open forum infectious diseases · 2026Article
- The incidence and antimicrobial resistance of Shigella-attributable diarrhoea in young children in low-income and middle-income countries from the multicountry Enterics for Global Health (EFGH) Shigella Surveillance Study: a prospective, facility-based hybrid surveillance study.The Lancet. Global health · 2026Article
- Risk factors associated with Shigella diarrhea in 6-35-month-olds: A cross-sectional study, Malawi, 2022-2024.PLOS global public health · 2026Article
- Shigellosis.Lancet (London, England) · 2025Review
- Article
- Exploring Natural Immune Responses toOpen forum infectious diseases · 2024Article
- ExploringVaccine: X · 2023Article
- Refining Immunogenicity through Intradermal Delivery of Outer Membrane Vesicles againstInternational journal of molecular sciences · 2023Article
- Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries.The Lancet. Global health · 2023Review
- Spatiotemporal variation in risk of Shigella infection in childhood: a global risk mapping and prediction model using individual participant data.The Lancet. Global health · 2023Article
- Toward aInternational journal of molecular sciences · 2023Review
- Frontiers inVaccines · 2022Article
- TheVaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 3 countries.
Funding
Abstract
Vaccine candidates for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.